GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: Collection effectiveness and cost effectiveness analysis

Abstract

Introduction

Plerixafor is a novel mobilizing agent of peripheral blood stem cells (PBSCs) in lymphoma and multiple myeloma (MM) patients whose cells mobilize poorly. Due to the substantial cost associated with its use, we aimed to compare the effectiveness and cost effectiveness of Plerixafor + GCSF (PG) versus GCSF ± Chemotherapy (GC) as salvage mobilization regimens.

Methods

The charts of consecutive lymphoma and MM patients who had undergone at least one previous attempt of PBSCs mobilization that failed or resulted in an insufficient cell dose for transplant between 2007 and 2010 were retrospectively reviewed. Patients identified received salvage mobilization with GC (prior to 2009) or PG after Plerixafor’s FDA approval. Data collected included demographics, medical histories, apheresis yields and transplant outcome. The cost effectiveness analysis was from the perspective of the Jordanian Ministry of Health. The incremental cost effectiveness ratio (ICER) was calculated by dividing the difference in cost by the difference in effectiveness for the two regimens.

Results

Five patients received GC and twelve received PG. A minimum CD34+ cell dose of 2 × 10⁶ cells/kg was collected from 8 patients (67%) in the PG group compared to 3 (60%) in the GC group (p=0.79). The average costs were US$8570 and US$25,700 for the GC group and the PG group, respectively. The ICER was US$244,714 per successful stem cell collection.

Conclusion

Salvage Plerixafor use showed a non-significant improvement in PBSCs collection with a significant increase in cost. Prospective comparative effectiveness studies are warranted to inform the optimal salvage mobilization regimen. To our knowledge, this is the first study from the Middle East to describe the effectiveness and cost effectiveness of Plerixafor.

Keywords

Plerixafor mobilization transplant cost effectiveness

Get full access to this article

View all access options for this article.

References

Bladé

Rosinoll

. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115: 3655–3663.

Vose

Anderson

KEssinger

. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846–1851.

Jantunen

Fruehauf

. Importance graft characteristics in auto-SCT:implications for optimizing mobilization regimens. Bone Marrow Transplant 2011; 46(5): 627–635.

Vose

Coiffier

. Advances in mobilization for the optimization of autologous stem cell transplantation. Leuk Lymphoma 2009; 50(9): 1412–1421.

Fernandez HF, Escalon MP, Pereira D, et al. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road? Bone Marrow Transplant 2007; 40(6): 505–513.

Ng Cashin

Shea

Mobilization of autologous peripheral blood hematopoietic cells for support of high-dose cancer therapy. In: Blume

(ed.) Thomas’ hematopoietic cell transplantation, 3rd ed. Malden, MA: Blackwell, 2004, pp. 576–576.

Barnett

Janossy

Lubenko

. Guidelines for the flow cytometric enumeration of CD34+ hemotopoietic stem cells. Prepared by the CD34+ haematopoietic stem cell working party. General Haematology Tas Force of the British Committee for Standards in Hematology. Clin Lab Haematol 1999; 21: 301–308.

Koenigsmann

Jentsch-Ullrich

Mohren

. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004; 44: 777–784.

Weaver

Schulman

Wilson-Relyea

. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000; 18(1): 43–43.

10.

DiPersio

Micallef

Stiff

. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27(28): 4767–4773.

11.

Perseghin

Terruzzi

Dassi

. Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. Transfus Apher Sci 2009; 41: 33–37.

12.

Demirer

Ayli

Ozcan

. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 468–474.

13.

DiPersio

Stadtmauer

Nademanee

. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.

14.

DiPersio

Micallef

Stiff

. Phase III prospective randomized double-blind placebo controlled trail of plerixafor plus granulocyte colony-stimulating factor compared with placebo granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.

15.

Duarte

Shaw

Marín

. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2011; 46(1): 52–58.

16.

Sutherland

Anderson

Keeney

. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5(3): 213–226.

17.

Schimd

Krall

Uittenbogaart

. Dead cell discrimination with 7-AAD in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry 1992; 13: 204–208.

18.

Philpott

Turner

AJC

Wesby

. The use of 7-AAD in identifying apoptosis: simplicity of use and broad spectrum application compared with other techniques. Blood 1996; 87: 2244–2251.

19.

Mononuclear cell (MNC) protocol in COBE spectra apheresis system: Cell Therapy Guide, Operator’s Manual, Section 2.1–2.20.

20.

Gee

Blood stem cell transplantation. In: Reiffers

Goldman

Armitage

(eds). Collection and processing of peripheral blood hematopoietic progenitor cells,, chapter 4. London: Martin Dunitz Ltd, 1998, pp. 55–72.

21.

Koenigsmann

Jentsch-Ullrich

Mohren

. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004; 44: 777–784.

22.

Rowley

. Hematopoietic stem cell cryopreservation: a review of current techniques. J Hematother 1992; 1: 233–250.

23.

Calandra

McCarty

McGuirk

. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41(4): 331–338.

24.

Weaver

Tauer

Zhen

. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother 1998; 7: 241–249.

25.

Apperley

Cook

Pagliuca

. Efficacy of plerixafor plus G-CSF for stem cell mobilization in patients with multiple myeloma or lymphoma who have failed prior mobilisation: a named patient program (NPP) evaluation. Haematologica 2010; 95(2): 212–212.

26.

Costa

Alexander

Hogan

. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64–69.

27.

Shaughnessy

Islas-Ohlmayer

Murphy

. Plerixafor plus G-CSF resulted in similar cost but more predictable days of apheresis compared to chemotherapy plus G-CSF for mobilization of autologous hematopoietic stem cells. Biol Blood Marrow Transplant 2010; 16(2): S203–S203.

28.

Campen

Armstrong

Christian

. Comparative cost-effectiveness of plerixafor plus granulocyte-colony stimulating factor versus cyclophosphamide plus granulocyte-colony stimulating for autologous peripheral blood stem cell mobilization in patients with non-hodgkin’s lymphoma. Biol Blood Marrow Transplant 2010; 16(2): S206–S206.

29.

Kymes

Pusik

Lambert

. Economic evaluation of plerixafor for stem cell mobilization. Am J Manage Care 2012; 18: 33–41.

30.

Tuffaha

Hussein

Abdel-Rahman

. Comparative cost utility analysis of plerixafor plus GCSF versus cyclophosphamide plus GCSF as salvage mobilization regimens in multiple myeloma patients. Biol Blood Marrow Transplant 2012; 18(2): S248–S248.